Quantcast

US WorldMeds Announces the Launch of Revonto(TM) (dantrolene sodium for injection)

July 6, 2010

LOUISVILLE, Ky., July 6 /PRNewswire/ — US WorldMeds is proud to announce the launch of Revonto(TM) (dantrolene sodium for injection), the first patented scientific advancement in the treatment of malignant hyperthermia (MH). The time to reconstitute dantrolene sodium for injection has been dramatically reduced to approximately 20 seconds or until the solution is clear. Revonto(TM) retains the cost-savings of the original dantrolene sodium for injection product while offering a significant improvement in pharmacotherapy.

“The enhanced reconstitution time is an important and critical scientific improvement to intravenous dantrolene sodium, the only available antidote for the treatment of malignant hyperthermia. MH is triggered in some patients by certain inhalation anesthetics during surgery. A rapid response to MH onset is critical because temperatures exceeding 105F degrees and death due to this condition can occur as early as 30 minutes from onset.” says Dr. George A. Digenis, Chief Scientific Officer of US WorldMeds.

Fatal and non-fatal liver disorders of an idiosyncratic or hypersensitivity type may occur with dantrolene sodium therapy. There have been reports of thrombophlebitis following administration of intravenous dantrolene. There have been rare reports of urticaria and erythema possibly associated with the administration of i.v. dantrolene sodium. For additional information, including the full prescribing information for Revonto(TM), please visit US WorldMeds’ website at www.revonto.com.

For more information on malignant hyperthermia, please visit The Malignant Hyperthermia Association of the United States (MHAUS) website at www.mhaus.org

Revonto(TM) will be available on GPO contracts as a dropship via your wholesaler/distributor.

For Ordering Information Call: 1.877.411.USWM(8796).

About US WorldMeds

US WorldMeds, LLC, a specialty pharmaceutical company located in Louisville, Kentucky, is committed to developing, licensing, and marketing unique and significant pharmaceuticals that address unmet medical needs. US WorldMeds is committed to using science to make lives better. For more information, please visit www.usworldmeds.com

SOURCE US WorldMeds


Source: newswire



comments powered by Disqus